Key result
Pharmacological inhibition of ASIC1a with the venom-derived peptide Hi1a significantly improved left ventricular developed pressure recovery to 60% of baseline compared to 20% in vehicle controls following ischemia-reperfusion injury.
Why the study?
ASIC1a is implicated in the injury response to cerebral ischemia, but little is known about its role in cardiac ischemia.
Does pharmacological inhibition of ASIC1a improve post-IRI cardiac viability and function in rodent and human models of cardiac ischemia?
Does pharmacological inhibition of ASIC1a improve post-IRI cardiac viability and function in rodent and human models of cardiac ischemia?
Absolute Event Rate: 60% vs 20%
p-value: p=<0.001
ASIC1a is a key mediator of cardiac ischemia-reperfusion injury and represents a potential therapeutic target for cardioprotection.
The proton-gated acid-sensing ion channel 1a (ASIC1a) is implicated in the injury response to cerebral ischemia but little is known about its role in cardiac ischemia. We provide genetic evidence that ASIC1a is involved in myocardial ischemia-reperfusion injury (IRI) and show that pharmacological inhibition of ASIC1a yields robust cardioprotection in rodent and human models of cardiac ischemia, resulting in improved post-IRI cardiac viability and function. Consistent with a key role for ASIC1a in cardiac ischemia, we show that polymorphisms in the ASIC1 genetic locus are strongly associated with myocardial infarction. Collectively, our data provide compelling evidence that ASIC1a is a key target for cardioprotective drugs to reduce the burden of disease associated with myocardial ischemia.
No takes yet. Share an insight, caveat, or question.
Redd et al. (2019) studied Myocardial ischemia-reperfusion injury. ASIC1a inhibition (Hi1a) vs. Vehicle control was evaluated on Left ventricular developed pressure (LVDP) recovery after 45 minutes of reperfusion (% of baseline) (p=<0.001). Pharmacological inhibition of ASIC1a with the venom-derived peptide Hi1a significantly improved left ventricular developed pressure recovery to 60% of baseline compared to 20% in vehicle controls following ischemia-reperfusion injury.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: